OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Monday. The brokerage issued a sell rating on the stock.

Several other equities analysts have also commented on the stock. Stephens reaffirmed an equal weight rating and set a $4.00 price target on shares of OncoCyte in a research report on Wednesday, April 17th. Needham & Company LLC increased their price objective on shares of OncoCyte from $3.60 to $4.25 and gave the stock a buy rating in a research report on Wednesday, April 24th. Finally, Benchmark reissued a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $4.06.

OncoCyte Stock Up 3.3 %

OncoCyte stock opened at $2.85 on Monday. The firm’s 50-day moving average is $2.83 and its two-hundred day moving average is $3.01. OncoCyte has a 12-month low of $2.08 and a 12-month high of $5.88.

Insider Activity at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Andrew Arno acquired 33,898 shares of OncoCyte stock in a transaction on Thursday, April 11th. The shares were purchased at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of OncoCyte stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The disclosure for this purchase can be found here. In the last three months, insiders bought 2,457,288 shares of company stock valued at $7,176,400. Corporate insiders own 1.94% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.